This comes as shocking news for VaxGen. FDA has postponed the advanced testing of anthrax vaccine being developed by the company. The second mid stage clinical trials of the vaccine were about to begin. The reason for this is that FDA found out the data submitted by the company was insufficient to prove that the stability of the product was enough for starting the clinical trials. This vaccine was meant to prevent diseases, which might be caused due to inhalation of anthrax spores, and as per the BioShield project, millions of doses of the vaccine had to be stocked. The company has still not stated how much time would be required for addressing the concerns of the FDA. This delay might lead to losses for the company as the order for stocks worth $1 billion by the Department of Health and Human Services might be terminated.